Analysts expect BioAge Labs, Inc. to report revenue of 7.87 M for 2026, against a range of 7.12 M to 8.61 M. The most recent reported year, 2025, came in at 8.99 M, a 30.9% beat against the 6.87 M consensus.
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 8.99 M | - | - | ||
| High Estimate | 0.00 | 7.20 M | 8.61 M | 17.71 M | ||
| Low Estimate | 0.00 | 6.54 M | 7.12 M | 15.68 M | ||
| Consensus Estimate | 0.00 | 6.87 M | 7.87 M | 16.70 M |
Analysts expect BioAge Labs, Inc. to report earnings per share of -2.35 for 2026, against a range of -2.46 to -2.24. The most recent reported year, 2025, came in at -2.24, a 6.3% beat against the -2.39 consensus.
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| Reported (Actual) | -6.63 | -2.24 | - | - | ||
| High Estimate | -3.33 | -2.15 | -2.24 | -1.90 | ||
| Low Estimate | -3.71 | -2.63 | -2.46 | -2.22 | ||
| Consensus Estimate | -3.52 | -2.39 | -2.35 | -2.06 |